Ormat Technologies, Inc. operates as a holding company. The firm engages in the geothermal and recovered energy power businesses. It operates through the following segments: Electricity, Product and Energy Storage. The Electricity segment focuses on the sale of electricity from the company's power plants pursuant to power purchase agreements. The Product segment involves the manufacture, including design and development, of turbines and power units for the supply of electrical energy and in the associated construction of power plants utilizing the power units manufactured by the company to supply energy from geothermal fields and other alternative energy sources. The Energy Storage segment consists of battery energy storage systems as a service and management of curtailable customer loads under contracts with U.S. retail energy providers and directly with large commercial and industrial customers. The company was founded in 1965 and is headquartered in Reno, NV.
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- Ora, a leading ophthalmic contract research organization, has appointed João "John" Trein, MD, MPH, as Therapeutic Lead, Posterior to strengthen its retinal disease and posterior segment drug development leadership. - Dr. Trein brings more than 20 years of clinical, surgical, and research experience across retinal conditions, including geographic atrophy, age-related macular degeneration, and diabetic retinopathy. - He will provide scientific and clinical leadership spanning clinical trial design, endpoint selection, patient identification, safety oversight, and study execution across Ora's posterior segment programs. - Dr. Trein continues to practice as a retina specialist at Aran Eye Associates in South Florida, keeping development strategies grounded in real-world patient needs.
- IBA, the world leader in particle accelerator technology, acquired Belgian radiochemistry company ORA for €15-20 million to expand its nuclear medicine capabilities. - The acquisition combines IBA's cyclotron leadership with ORA's NEPTIS® radiopharmaceutical synthesizer technology to create integrated solutions for hospitals and radiopharmacy networks. - This strategic move reinforces IBA's position in precision oncology and complements existing initiatives including PanTera's Ac-225 production and collaborations for At-211 development. - The transaction is expected to be immediately accretive to revenue and EBITDA while advancing the translation of nuclear medicine solutions from research to clinical practice.
• Diagnos Inc announces plans to file FDA pre-market authorization for CARA SYSTEM, an AI-powered medical device designed for early detection of multiple retinal diseases. • The company has partnered with ORA, a specialized clinical research organization, to navigate the FDA regulatory process for their machine-learning-enabled medical device. • The technology aims to assist healthcare professionals in analyzing fundus images for diabetic retinopathy, age-related macular degeneration, and hypertensive retinopathy detection.
